Trial · NCT05468268

Noninvasive Brain Stimulation for pAD

NCT05468268, Not applicable, Unknown, Università degli Studi di Trento

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. Noninvasive Brain Stimulation for pAD. Trials, record NCT05468268. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05468268

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Noninvasive Brain Stimulation for pAD
NCT number: NCT05468268
Status: Unknown
Phases: Not applicable
Enrollment: 40 participants, estimated
Lead sponsor: Università degli Studi di Trento
Conditions: Alzheimer's Disease - MCI
Interventions: 20 Hz rTMS, Sham rTMS
First posted: 2022-07-21
Last updated: 2022-07-21

Source ClinicalTrials.gov

Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	TMS evoked potentials - TEPs changes. Analysis of cortical excitability and inhibition changes	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16)	180 pulses will be delivered to the target area (left DLPFC) during EEG registration. This outcome will analyze cortical excitability and inhibition changes induced in the state of excitability/inhibition of brain circuits following the TMS impulse. The amplitude will be used as a marker of cortical excitability.
Primary	Connectivity Index, cortico-cortical connectivity analysis: changes in the connectivity evoked by TMS	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16)	180 pulses will be delivered to the target area (left DLPFC) during EEG registration. This outcome will analyze changes in the latencies and topographical distribution of the TEPs thus providing a connectivity index. This connectivity index will be used to infer the propagation of the activity from the stimulation site to functionally connected areas.
Primary	TMS evoked oscillations changes	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16)	180 pulses will be delivered to the target area (left DLPFC) during EEG registration. This outcome will analyze changes in responses induced by TMS in the frequency domain for the intrinsic capacity of the stimulated area to generate oscillatory activity in specific frequency bands
Primary	Autobiographical Memory Interview: change in performance	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)]	The Autobiographical Memory Interview is a method of assessing autobiographical memory using a text-based analysis of transcribed autobiographical protocols. The script is segmented into internal (temporally and contextually specific) details and external (generic or semantic) details, which are then tallied. Internal scores are conceptualized as reflecting the episodic richness of the mental simulation, whereas external scores include non-episodic components of the mental simulation such as generic information, routine simulations, or verbal artifacts like repetitions. Mean changes on test scores: \[score ranges min=N/A, max= no limit, higher score=better outcome\]
Primary	Free and Cued Selective Recall Reminding Test - episodic memory: change in performance	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)]	Free and Cued Selective Recall Reminding Test: the three measures being evaluated include free recall (the cumulative sum of free recall from the trials; range 0-48), total recall (the cumulative sum of free recall + cued recall from the trials, range 0-48), and cue efficiency (total recall-free recall)/(48-free recall, range 0.0-1.0). Mean changes on test scores: \[higher score=better outcome\]
Primary	Montreal Cognitive Assessment Test - cognitive screening: change in performance	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)]	Scores on the Montreal Cognitive Assessment Test range from zero to 30. A score of 26 and higher is considered normal. If the score is below 25, the result indicates a possible cognitive impairment. Mean changes in test scores: \[higher score=better outcome\]
Secondary	Raven's Coloured Progressive Matrices™: change in performance	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)]	Evaluation of abstract non-verbal reasoning: mean changes in test scores \[score range 0-36, higher score=better outcome\]
Secondary	Forward Digit Span and Reverse Digit Span: change in performance	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)]	Evaluation of short and long term memory (verbal) - Mean changes in test scores \[score range 0-9, higher score=better outcome\]
Secondary	Spatial Span: change in performance	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)]	Evaluation of short and long term memory (visuospatial) Mean changes in test scores \[score range 0-10, higher score=better outcome\]
Secondary	Prose Memory: change in performance	Prior to treatment (baseline=t0=week 1), at the end of the 10 days rTMS phase (t1=Week 4), 3 months post-treatment (t2=Week 16), & 6 months post treatment (t3=Week 28)]	Evaluation of short and long term memory - Mean changes in test scores \[score range 0-28, higher score=better outcome\];

1 to 10 of 18Source ClinicalTrials.gov

See all 18 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers10

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
16517514	BACKGROUND	PubMed
17188568	BACKGROUND	PubMed
19833552	BACKGROUND	PubMed
21514250	BACKGROUND	PubMed
25541459	BACKGROUND	PubMed
26275346	BACKGROUND	PubMed
33188680	BACKGROUND	PubMed
33243615	BACKGROUND	PubMed
35074394	BACKGROUND	PubMed
35101524	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests11

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
Cancellation Test	Secondary outcome	ConductCognition
Category Fluency	Secondary outcome	ConductCognition
Complex Figure Copy and Recall	Secondary outcome	ConductCognition
Digit Span Test	Secondary outcome	ConductCognition
Matrix Reasoning	Secondary outcome	ConductCognition
Selective Reminding Task	Secondary outcome	ConductCognition
Stroop Color-Word Test	Secondary outcome	ConductCognition
Token Commands Task	Secondary outcome	ConductCognition
Trail Making Test A	Secondary outcome	ConductCognition
Trail Making Test B	Secondary outcome	ConductCognition

1 to 10 of 11

See all 11 tests

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05468268

GET https://conductscience.org/api/trials/v1/NCT05468268/registered

API reference For AI assistants